← Eichor
Study identifier: NCT07740564 Synced from ClinicalTrials.gov · July 31, 2026
● Not Yet Recruiting

Phase III Study of OT202 in Treating Moderate to Severe Dry Eye

Condition: Dry Eye  ·  Sponsor: Ocumension Therapeutics (Suzhou) Co., Ltd

PhasePhase 3
Planned participants842
Who can joinAll sexes, 30 Years to 75 Years
Healthy volunteersNo

About this study

This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial, enrolling 842 subjects with moderate to severe dry eye, who will be randomized at a 1:1 ratio to receive either 1% OT202 ophthalmic solution or vehicle control. The trial consists of screening, run-in, 8-week double-blind treatment period, and three long-term safety follow-up cohorts (10 weeks, 28 weeks, and 54 weeks), including 342 subjects for the 10-week follow-up, 350 subjects for the 28-week follow-up, and 150 subjects for the 54-week follow-up. Unblinding will be performed after the completion of double-blind treatment for all subjects, who will then receive open-label 1% OT202 ophthalmic solution uniformly. The co-primary efficacy endpoints are the change from baseline in Total Corneal Fluorescein Staining Score (TCSS) and Visual Analog Scale-Eye Dryness Score (VAS-EDS) at Day 56. Pharmacokinetic assessments will be conducted in 60 of the subjects assigned to the 54-weeks long-term safety follow-up. An interim futility analysis will be performed once approximately 30% of subjects complete the treatment period. Analysis of covariance (ANCOVA) will be utilized for efficacy statistical analyses. The primary objective is to evaluate the efficacy and safety of OT202 ophthalmic solution in the treatment of moderate to severe dry eye.

This description comes directly from the study's public registry record.

Talk to the study team

Wei Chen  ·  0577-88075582  ·  chenwei@eye.ac.cn

Jia Qu  ·  0577-88068888  ·  jia.qu@163.com

Always discuss trial participation with your own doctor first.

Locations (49)

The First Affiliated Hospital of Bengbu Medical UniversityBengbu, Anhui, China
The Second Affiliated Hospital of Anhui Medical UniversityHefei, Anhui, China
Peking University People's HospitalBeijing, Beijing Municipality, China
Peking Union Medical College HospitalBeijing, Beijing Municipality, China
Chongqing Aier Eye HospitalChongqing, Chongqing Municipality, China
The First Affiliated Hospital of Fujian Medical UniversityFuzhou, Fujian, China
Xiamen Eye Center Affiliated to Xiamen UniversityXiamen, Fujian, China
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityGuangzhou, Guangdong, China
Shantou International Eye Center of Shantou University and The Chinese University of Hong KongShantou, Guangdong, China
Shenzhen Eye HospitalShenzhen, Guangdong, China
The People's Hospital of Guangxi Zhuang Autonomous RegionNanning, Guangxi, China
The First Affiliated Hospital of Guizhou University of Traditional Chinese MedicineGuiyang, Guizhou, China

+ 37 more locations — full list on the registry record.

Follow this study

Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.

We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07740564